Efficacy of eculizumab in refractory life‐threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia

Eculizumab may be considered as an emergency therapeutic option in refractory life‐threatening warm autoimmune hemolytic anemia especially if direct antiglobulin test is positive for both IgG and C3d and after failure of all conventional treatments.

Detalles Bibliográficos
Autores principales: Gauchy, Anne‐Cécile, Hentzien, Maxime, Wynckel, Alain, de Marcellus, Victoire, Rodier, Cyrielle, Delmer, Alain, Quinquenel, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752594/
https://www.ncbi.nlm.nih.gov/pubmed/33363796
http://dx.doi.org/10.1002/ccr3.3250
_version_ 1783625898914742272
author Gauchy, Anne‐Cécile
Hentzien, Maxime
Wynckel, Alain
de Marcellus, Victoire
Rodier, Cyrielle
Delmer, Alain
Quinquenel, Anne
author_facet Gauchy, Anne‐Cécile
Hentzien, Maxime
Wynckel, Alain
de Marcellus, Victoire
Rodier, Cyrielle
Delmer, Alain
Quinquenel, Anne
author_sort Gauchy, Anne‐Cécile
collection PubMed
description Eculizumab may be considered as an emergency therapeutic option in refractory life‐threatening warm autoimmune hemolytic anemia especially if direct antiglobulin test is positive for both IgG and C3d and after failure of all conventional treatments.
format Online
Article
Text
id pubmed-7752594
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-77525942020-12-23 Efficacy of eculizumab in refractory life‐threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia Gauchy, Anne‐Cécile Hentzien, Maxime Wynckel, Alain de Marcellus, Victoire Rodier, Cyrielle Delmer, Alain Quinquenel, Anne Clin Case Rep Case Reports Eculizumab may be considered as an emergency therapeutic option in refractory life‐threatening warm autoimmune hemolytic anemia especially if direct antiglobulin test is positive for both IgG and C3d and after failure of all conventional treatments. John Wiley and Sons Inc. 2020-08-17 /pmc/articles/PMC7752594/ /pubmed/33363796 http://dx.doi.org/10.1002/ccr3.3250 Text en © 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Gauchy, Anne‐Cécile
Hentzien, Maxime
Wynckel, Alain
de Marcellus, Victoire
Rodier, Cyrielle
Delmer, Alain
Quinquenel, Anne
Efficacy of eculizumab in refractory life‐threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia
title Efficacy of eculizumab in refractory life‐threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia
title_full Efficacy of eculizumab in refractory life‐threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia
title_fullStr Efficacy of eculizumab in refractory life‐threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia
title_full_unstemmed Efficacy of eculizumab in refractory life‐threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia
title_short Efficacy of eculizumab in refractory life‐threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia
title_sort efficacy of eculizumab in refractory life‐threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752594/
https://www.ncbi.nlm.nih.gov/pubmed/33363796
http://dx.doi.org/10.1002/ccr3.3250
work_keys_str_mv AT gauchyannececile efficacyofeculizumabinrefractorylifethreateningwarmautoimmunehemolyticanemiaassociatedwithchronicmyelomonocyticleukemia
AT hentzienmaxime efficacyofeculizumabinrefractorylifethreateningwarmautoimmunehemolyticanemiaassociatedwithchronicmyelomonocyticleukemia
AT wynckelalain efficacyofeculizumabinrefractorylifethreateningwarmautoimmunehemolyticanemiaassociatedwithchronicmyelomonocyticleukemia
AT demarcellusvictoire efficacyofeculizumabinrefractorylifethreateningwarmautoimmunehemolyticanemiaassociatedwithchronicmyelomonocyticleukemia
AT rodiercyrielle efficacyofeculizumabinrefractorylifethreateningwarmautoimmunehemolyticanemiaassociatedwithchronicmyelomonocyticleukemia
AT delmeralain efficacyofeculizumabinrefractorylifethreateningwarmautoimmunehemolyticanemiaassociatedwithchronicmyelomonocyticleukemia
AT quinquenelanne efficacyofeculizumabinrefractorylifethreateningwarmautoimmunehemolyticanemiaassociatedwithchronicmyelomonocyticleukemia

Ejemplares similares